Ascension Ventures, the strategic investment arm of healthcare provider Ascension, has led a $25m series C round for US-based precision medicine technology developer Syapse.
Social Capital Partnership and Safeguard Scientifics also contributed to the round, which increased the company’s total funding to $39.5m. Social Capital Partnership led its $3m series A round in 2013 before joining Safeguard for a $10m series B the following year.
Syapse has created a software suite that allows health systems to streamline their operations, improve clinical results and incorporate new payment models. It will use the funding to expand the reach of its oncology platform, the Syapse Precision Medicine Platform.
Matt Hermann, senior managing director of Ascension Ventures, said: “Syapse enables community providers to achieve a core objective that guides both Ascension Ventures and its partner health systems: providing compassionate, personalised care with reverence for the uniqueness of each individual.”